

Connecting via Winsock to STN

2/25/05

10/635,040a

Welcome to STN International! Enter x:x

Structure Search

LOGINID:SSSPTAAJP1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2



* * * * * Welcome to STN International * * * * *

- NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
- NEWS 2 "Ask CAS" for self-help around the clock
- NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover *61=0*
- NEWS 4 OCT 28 KOREAPAT now available on STN
- NEWS 5 NOV 30 PHAR reloaded with additional data
- NEWS 6 DEC 01 LISA now available on STN
- NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
- NEWS 8 DEC 15 MEDLINE update schedule for December 2004
- NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
- NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
- NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
- NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
- NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
- NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
- NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
- NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and February 2005
- NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
- NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
- NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
- NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
- NEWS HOURS STN Operating Hours Plus Help Desk Availability
- NEWS INTER General Internet Information
- NEWS LOGIN Welcome Banner and News Items
- NEWS PHONE Direct Dial and Telecommunication Network Access to STN
- NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:01:01 ON 25 FEB 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:01:09 ON 25 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8

DICTIONARY FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10635040a.str



chain nodes :

10 11 12 13 14 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

1-10 3-15 9-16 10-12 11-12 12-13 14-15 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-10 5-7 6-9 7-8 8-9 9-16 10-12 11-12

exact bonds :
3-15 12-13 14-15 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :

10:= exact 1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 14:01:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:01:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS
SEARCH TIME: 00.00.01

39 ANSWERS

L3 39 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 14:01:39 ON 25 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2005 VOL 142 ISS 10

FILE LAST UPDATED: 24 Feb 2005 (20050224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3

L4 9 L3

=> d L4 iib abs hitstr 1-9

'IIB' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

 OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

 SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

 HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):end

=> d L4 ibib abs hitstr 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:80529 CAPLUS
 DOCUMENT NUMBER: 140:133861
 TITLE: ADP antagonists and ACAT inhibitors for treating
 arteriosclerosis
 INVENTOR(S): Asai, Fumitoshi; Inaba, Toshimori; Ogawa, Taketoshi
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009119	A1	20040129	WO 2003-JP9108	20030717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

*co-pending
 OIBP
 no common inventor
 but shared
 assignee*

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004051639 A2 20040219 JP 2003-275276 20030716

PRIORITY APPLN. INFO.:

JP 2002-209165 A 20020718

AB A medicinal composition characterized in that an ADP receptor antagonist and an ACAT inhibitor, are administered either simultaneously or sep. at a definite interval. The medicinal composition is useful as a preventive or a remedy for arteriosclerosis or diseases derived from arteriosclerosis, such as ischemic heart disease, ischemic brain disease, and peripheral circulation failure in warm-blooded animals (in particular, humans). For example, pharmacol. activities of 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt (II) were studied using rabbits and tablets containing I 10 mg and II 30 mg each were formulated.


IT 189198-30-9 189198-32-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ADP antagonists and ACAT inhibitors for treatment of arteriosclerosis and related disorders thereof)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3



CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:818314 CAPLUS

DOCUMENT NUMBER: 139:297051

TITLE: Medicinal composition comprising ACAT inhibitor and insulin resistance improving agent

INVENTOR(S): Inaba, Toshimori; Fujiwara, Toshihiko

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084572	A1	20031016	WO 2003-JP4296	20030403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481379	AA	20031016	CA 2003-2481379	20030403
BR 2003008871	A	20050104	BR 2003-8871	20030403
EP 1493448	A1	20050105	EP 2003-745697	20030403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004002365	A2	20040108	JP 2003-101076	20030404
PRIORITY APPLN. INFO.:			JP 2002-103134	A 20020405
			WO 2003-JP4296	W 20030403

AB It is intended to provide a medicinal composition for preventing or treating arteriosclerosis or diseases caused by arteriosclerosis which comprises an ACAT inhibitor and an insulin resistance improving agent. For example, tablets were formulated containing 5-[[4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide hemisulfate 10, lactose 113, starch 25, and Mg stearate 2 mg/tablet.

IT 189198-30-9 608510-47-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal composition comprising ACAT inhibitor and insulin resistance improving agent)

RN 189198-30-9 CAPLUS

ODP

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



yes


RN 608510-47-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3




yes

CM 2

CRN 7664-93-9

CMF H2 O4 S



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202511 CAPLUS

DOCUMENT NUMBER: 138:226765

TITLE: Medicinal compositions containing angiotensin II receptor antagonists

INVENTOR(S): Sada, Toshio; Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 26 pp.

ODP

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

CODEN: PIXXD2
Patent
Japanese

ODP

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020315	A1	20030313	WO 2002-JP8629	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003146907	A2	20030521	JP 2002-246112	20020827
EP 1421953	A1	20040526	EP 2002-762874	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012254	A	20041019	BR 2002-12254	20020827
US 2004198788	A1	20041007	US 2004-789340	20040226
PRIORITY APPEN. INFO.:				
			JP 2001-257435	A 20010828
			WO 2002-JP8629	W 20020827

AB Disclosed are medicinal compns. for administering an angiotensin II receptor antagonist and an ACAT inhibitor either at the same time or sep. at a certain interval. The compns. are effective for the prevention and treatment of arteriosclerosis and cardiac ischemia. For example, tablets were formulated containing olmesartan 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide 10, lactose 113, starch 25, and Mg stearate 2 mg/each.


IT 189198-30-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal compns. containing angiotensin II receptor antagonist and ACAT inhibitor)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



Yel

REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:792270 CAPLUS


DOCUMENT NUMBER: 137:310809

TITLE: Preparation of indolines as intermediates for preparation of ACAT inhibitors
 INVENTOR(S): Tanabe, Hideo; Oyama, Yuzuru; Kiyota, Hiroshi
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002302481	A2	20021018	JP 2002-24876	20020201
PRIORITY APPLN. INFO.: OTHER SOURCE(S): GI		MARPAT 137:310809	JP 2001-26375	A 20010202

(*ans is 2001-26374*)

OSP



yes



yes

AB The compds. I (R1, R2 = lower alkyl; R3 = octyl) or their salts are prepared by deprotection of I (R1, R2 = lower alkyl; R3 = amino-protecting group) or their salts and octylation of I (R1, R2 = lower alkyl; R3 = H) or their salts. Carboxyindolines II (R1, R2 = lower alkyl) are prepared from I (R1, R2 = lower alkyl; R3 = octyl). N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was reacted with NaOMe in MeOH under reflux for 6 h, alkylated with octyl bromide in the presence of (iso-Pr)2NEt in xylene under reflux for 12 h, hydrolyzed in the presence of aqueous NaOH in ProH under reflux for 15 h, and treated with H2SO4 in acetone-H2O mixture to give 83% N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

IT 189198-32-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolines as intermediates for preparation of ACAT inhibitors)

RN 189198-32-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S




L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:716126 CAPLUS
DOCUMENT NUMBER: 137:252985
TITLE: Medicinal compositions containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors
INVENTOR(S): Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072147	A1	20020919	WO 2002-JP2311	20020312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

Handwritten signature 'asp' is present next to the table.

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 JP 2002338496 A2 20021127 JP 2002-67841 20020313
 PRIORITY APPLN. INFO.: JP 2001-72050 A 20010314
 AB Disclosed are medicinal compns. for administering an ileal bile acid
 transporter inhibitor and a cholesterol acyltransferase (ACAT) inhibitor
 either at the same time or sep. at a certain interval. The effect of oral
 administration of both 4-[3-[(1-(3,5-difluorophenyl)ethylamino)-(4-
 methoxyphenyl)methyl]phenylamino]-3-hydroxy-3-cyclobutene-1,2-dione (I)
 and N-(1-octyl-5-carboxymethyl-4,6-dimethylindoline-7-yl)-2,2-
 dimethylpropaneamide (II) on blood serum triglyceride was prepared Also, a
 tablet containing I 50, II 30, lactose 368, corn starch 50, magnesium stearate
 2 mg was prepared
 IT **189198-30-9**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (hypolipemic compns. containing bile acid transporter inhibitor and
 cholesterol acyltransferase inhibitors)
 RN 189198-30-9 CAPLUS
 CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-
 4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:615568 CAPLUS

DOCUMENT NUMBER: 137:169415

TITLE: Preparation of indoline derivatives as acyl-coenzyme
 A:cholesterol acyltransferase inhibitors

INVENTOR(S): Tomori, Hiroshi; Miyamoto, Hiroshi; Fukuhara, Hiroshi;
 Sonobe, Ryuichi; Miura, Motoko; Shimura, Kazuhiko;
 Fujimoto, Katsuhiko; Wakayama, Masakazu

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062758	A1	20020815	WO 2002-JP804	20020201
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2437134	AA	20020815	CA 2002-2437134	20020201
JP 2002302482	A2	20021018	JP 2002-24877	20020201

EP 1364942 A1 20031126 EP 2002-710441 20020201
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI, CY, TR
 US 2004058979 A1 20040325 US 2003-635040 20030731
 NO 2003003432 A 20031001 NO 2003-3432 20030801
 PRIORITY APPLN. INFO.: JP 2001-26374 A 20010202
 WO 2002-JP804 W 20020201
 OTHER SOURCE(S): CASREACT 137:169415; MARPAT 137:169415
 GI



gen app

AB Novel intermediates such as I and II useful for synthesizing an indoline derivative having excellent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity are prepared (R1 = an amino-protecting group; R2 and R3 = lower alkyl; and R4 = H or a carboxy-protecting group). Reaction of 1-acetyl-4,6-dimethylindoline with glyoxylic acid, hydrogenolysis with Pd-C and esterification with saturated HCl-EtOH solution, followed by

nitration, hydrogenation, reaction with pivaloyl chloride, deacetylation, reaction with octyl bromide and base hydrolysis gave N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt.

IT **189198-32-1P**


RL: SPN (Synthetic preparation); PREP (Preparation)
 (indoline derivative useful for ACAT inhibitor and their preparation)

RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9
 CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9
 CMF H2 O4 S



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:184896 CAPLUS

DOCUMENT NUMBER: 136:236854

TITLE: Medicinal compositions for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors

INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020009	A1	20020314	WO 2001-JP7438	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001082541	A5	20020322	AU 2001-82541	20010829
CA 2420951	AA	20030228	CA 2001-2420951	20010829
EP 1314423	A1	20030528	EP 2001-961177	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 524406	A	20040625	NZ 2001-524406	20010829
BR 2001013523	A	20040629	BR 2001-13523	20010829
RU 2246302	C2	20050220	RU 2003-105835	20010829
US 2002055533	A1	20020509	US 2001-943712	20010831
JP 2002145774	A2	20020522	JP 2001-262600	20010831
ZA 2003001543	A	20040609	ZA 2003-1543	20030225
NO 2003000946	A	20030408	NO 2003-946	20030228
US 2004092571	A1	20040513	US 2003-702930	20031105

PRIORITY APPLN. INFO.:

JP 2000-265082	A	20000901
US 2000-230601P	P	20000906
WO 2001-JP7438	W	20010829
US 2001-943712	B1	20010831

AB Disclosed are medicinal compns. for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an HMG-CoA reductase inhibitor either at the same time or sep. after a definite period of time. Blood lipid-lowering effect of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and pravastatin 3 mg/kg in hamsters was examined Also, tablet containing I 30, sodium pravastatin 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT 189198-32-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

*PROV antedates
1A by
7 1 yr
has end
compd*

*our
1A=
2/1/02*

*date =
no*

(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S




IT 189198-30-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:113163 CAPLUS
 DOCUMENT NUMBER: 136:167280
 TITLE: Preparation of 5-carboxymethylindolines
 INVENTOR(S): Kamiya, Shoji; Matsui, Hiroshi
 PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

different inventor assignee

PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2002047269 A2 20020212 JP 2000-233250 20000801
 PRIORITY APPLN. INFO.: JP 2000-233250 20000801
 OTHER SOURCE(S): CASREACT 136:167280; MARPAT 136:167280
 GI



AB The compds. I (Y = CO₂H; R₁ = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R₂, R₃, R₅ = H, lower alkyl, lower alkoxy; R₄ = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, etc.; A = alkylene; Z = CH₂CH₂, CH:CH) or their salts, as ACAT and lipid peroxidn. inhibitors, are prepared by carbamoylation of cyano compds. I (Y = cyano; R₁ = protecting group; R₂, R₃, R₅, A, Z = same as above), reaction of I (Y = CONH₂; R₁ = H; R₂, R₃, R₅, A, Z = same as above) or their salts with R₁X (R₁ = same as above; X = leaving group), and carboxylation of I (Y = CONH₂; R₁ = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R₂, R₃, R₅, A, Z = same as above) or their salts. N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was treated with NaOH in MeOH under reflux for 20 h and alkylated with n-octyl bromide in DMF in the presence of K₂CO₃ and KI at 40° for 24 h to give N-(5-carbamoylmethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide, which was treated with NaOH in PrOH at 90-100° for 12 h to give 98% N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfate .

IT 189198-32-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of carboxymethylindolines)


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3




yes

CM 2

CRN 7664-93-9

CMF H2 O4 S



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:326877 CAPLUS

DOCUMENT NUMBER: 126:305540

TITLE: Preparation of benzene-fused heterocyclic derivatives as inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) and medicinal use thereof

INVENTOR(S): Kamiya, Shoji; Shirahase, Hiroaki; Matsui, Hiroshi; Nakamura, Shohei; Wada, Katsuo

PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9712860	A1	19970410	WO 1996-JP2852	19960930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
CA 2233842	AA	19970410	CA 1996-2233842	19960930
AU 9670977	A1	19970428	AU 1996-70977	19960930
AU 708571	B2	19990805		
EP 866059	A1	19980923	EP 1996-932060	19960930
EP 866059	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1203587	A	19981230	CN 1996-198670	19960930
CN 1097043	B	20021225		
BR 9610846	A	19990713	BR 1996-10846	19960930


on
1449

JP 2968050 B2 19991025 JP 1996-514152 19960930
 RU 2173316 C2 20010910 RU 1998-108605 19960930
 IL 123939 A1 20011125 IL 1996-123939 19960930
 AT 210116 E 20011215 AT 1996-932060 19960930
 ES 2164920 T3 20020301 ES 1996-932060 19960930
 PT 866059 T 20020328 PT 1996-932060 19960930
 CZ 292632 B6 20031112 CZ 1998-996 19960930
 TW 429250 B 20010411 TW 1996-85112125 19961004
 NO 9801485 A 19980602 NO 1998-1485 19980401
 US 6063806 A 20000516 US 1998-51202 19980403
 HK 1015781 A1 20030822 HK 1999-100913 19990305
 US 6200988 B1 20010313 US 2000-506839 20000218
 CN 1361100 A 20020731 CN 2001-142957 20011130

PRIORITY APPLN. INFO.:

JP 1995-259082 A 19951005
 JP 1996-58018 A 19960314
 JP 1996-194331 A 19960724
 WO 1996-JP2852 W 19960930

OTHER SOURCE(S): MARPAT 126:305540
 GI



I

AB Heterocyclic derivs. represented by general formula (I; one of R1, R2, and R5 = OH, CO2H, alkoxycarbonyl, NR9R10, or alkyl or alkenyl substituted by OH, acidic group, or NR9R10 and the others = H, lower alkyl or alkoxy; wherein R9, R10 = H, lower alkyl; one of R3 and R4 = NHCOR7 and the other = H, lower alkyl or alkoxy; wherein R7 = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, NHR8; wherein R8 = alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R6 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl; Z = a linkage group required to form a 5- to 6-membered ring together with NR6 and C atoms of the benzene ring) or pharmaceutically acceptable salts thereof are prepared. The compds. or pharmaceutically acceptable salts thereof show excellent effects of inhibiting ACAT and inhibiting the peroxidn. of lipids on mammals and thus are useful as ACAT inhibitors and lipid peroxidn. inhibitors. Namely, they are useful in the prevention and treatment of, for example, arteriosclerosis, hyperlipemia, arteriosclerotic lesions in association with diabetes, and ischemic diseases in brain and heart. Thus, N-(1-acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was heated with AcOK in MeCN/DMF at 60° under stirring for 1 h, followed by saponification with NaOH in aqueous EtOH under reflux, to give N-(5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide, which was alkylated by 1-iodooctane in the presence of K2CO3 in DMF to give at 50° for 2 h N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide (II). II in vitro inhibited by 99.2% the production of cholesteryl oleate from [1-14C]oleoyl CoA in microsome fraction of rabbit small intestinal membrane and at 10 mg/kg per day for 3 days in vivo lowered by 57.1% a total serum cholesterol in rats fed with a high cholesterol diet.


IT 189198-30-9P 189198-31-0P 189198-32-1P
 189198-33-2P 189198-34-3P 189198-49-0P

189198-55-8P 189198-58-1P 189198-59-2P
 189198-60-5P 189198-61-6P 189198-62-7P
 189198-63-8P 189198-64-9P 189198-65-0P
 189198-66-1P 189198-68-3P 189198-69-4P
 189198-71-8P 189198-72-9P 189198-74-1P
 189198-75-2P 189198-77-4P 189198-78-5P
 189198-79-6P 189198-80-9P 189198-82-1P
 189198-83-2P 189198-84-3P 189198-85-4P
 189198-95-6P 189198-96-7P 189198-97-8P
 189198-98-9P 189199-33-5P 189199-34-6P
 189199-36-8P 189199-38-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzene-fused heterocyclic derivs. as inhibitor of acyl-CoA:cholesterol acyltransferase and lipid peroxidn. for disease therapy)

RN 189198-30-9 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



Yes

RN 189198-31-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monohydrochloride (9CI) (CA INDEX NAME)



Yes

● HCl


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 189198-33-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2


CRN 7697-37-2

CMF H N O3



RN 189198-34-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monosodium salt (9CI) (CA INDEX NAME)




yes

● Na

RN 189198-49-0 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



homolog


RN 189198-55-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(6-methylheptyl)- (9CI) (CA INDEX NAME)



RN 189198-58-1 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-nonyl- (9CI) (CA INDEX NAME)



homolog

RN 189198-59-2 CAPLUS



CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(7-methyloctyl)- (9CI) (CA INDEX NAME)



homolog (isomer)


RN 189198-60-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(5-ethylheptyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-61-6 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-62-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(8-methylnonyl)- (9CI) (CA INDEX NAME)




RN 189198-63-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-undecyl- (9CI) (CA INDEX NAME)




RN 189198-64-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(9-methyldecyl)- (9CI) (CA INDEX NAME)




RN 189198-65-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-dodecyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-66-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(10-methylundecyl)- (9CI) (CA INDEX NAME)




RN 189198-68-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-69-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-71-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-72-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-74-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-75-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-77-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-1-heptyl- (9CI) (CA INDEX NAME)




RN 189198-78-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-79-6 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-nonyl- (9CI) (CA INDEX NAME)




RN 189198-80-9 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 189198-82-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 189198-83-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-84-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-nonyl- (9CI) (CA INDEX NAME)




RN 189198-85-4 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 189198-95-6 CAPLUS

CN 1H-Indole-5-acetic acid, 1-heptyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-96-7 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-octyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-97-8 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-nonyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-98-9 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189199-33-5 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-7-[(3-methoxy-1-oxopropyl)amino]-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-34-6 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-7-[[3-(methylthio)-1-oxopropyl]amino]-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-36-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(cyclohexylacetyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189199-38-0 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-1-octyl-7-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

44.91

206.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.57

-6.57

STN INTERNATIONAL LOGOFF AT 14:02:27 ON 25 FEB 2005